|
Taysha Gene Therapies Inc
|
Sukumar Nagendran
|
Director, President and Head of R&D |
Sale of securities on an exchange or to another person at price $ 6.24 per share. |
10 Jul 2026 |
200,000 |
936,410
|
-
|
6.2 |
1,248,000
|
Common Stock |
|
Anixa Biosciences Inc
|
Amit Kumar
|
Director, Chief Executive Officer |
Purchase of securities on an exchange or from another person at price $ 3.04 per share. |
10 Jul 2026 |
5,000 |
635,812
(3%)
|
0%
|
3.0 |
15,200
|
Common Stock |
|
Cue Biopharma Inc
|
Shao-Lee Lin
|
Director, Chief Executive Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
09 Jul 2026 |
327,537 |
655,074
(2%)
|
1%
|
|
0
|
Common Stock |
|
Cue Biopharma Inc
|
Shao-Lee Lin
|
Director, Chief Executive Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
09 Jul 2026 |
327,537 |
327,537
|
-
|
|
-
|
Common Stock |
|
Cue Biopharma Inc
|
Sumita Ray
|
Chief Legal Compliance Officer, Corporate Secretary |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
09 Jul 2026 |
54,589 |
54,589
|
-
|
|
-
|
Common Stock |
|
Cue Biopharma Inc
|
Sumita Ray
|
Chief Legal Compliance Officer, Corporate Secretary |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
09 Jul 2026 |
54,589 |
109,178
(0%)
|
0%
|
|
0
|
Common Stock |
|
Cue Biopharma Inc
|
Michael Meluzio
|
VP, Prin. Accounting Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
09 Jul 2026 |
40,942 |
40,942
(0%)
|
0%
|
|
0
|
Common Stock |
|
Cue Biopharma Inc
|
Michael Meluzio
|
VP, Prin. Accounting Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
09 Jul 2026 |
40,942 |
40,942
|
-
|
|
-
|
Common Stock |
|
Cue Biopharma Inc
|
Daniel A. Camardo
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
09 Jul 2026 |
21,800 |
21,800
(0%)
|
0%
|
|
0
|
Common Stock |
|
Cue Biopharma Inc
|
Pamela D. Garzone
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
09 Jul 2026 |
21,800 |
21,800
(0%)
|
0%
|
|
0
|
Common Stock |
|
Cue Biopharma Inc
|
Pasha Sarraf
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
09 Jul 2026 |
21,800 |
32,595
(0%)
|
0%
|
|
0
|
Common Stock |
|
Cue Biopharma Inc
|
Viola Mong Meehan
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
09 Jul 2026 |
21,800 |
21,800
(0%)
|
0%
|
|
0
|
Common Stock |
|
Alector Inc
|
Grace Wong-Sarad
|
Principal Accounting Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
09 Jul 2026 |
20,000 |
115,461
(0%)
|
0%
|
|
0
|
Common Stock |
|
UroGen Pharma Ltd
|
Mark P. Schoenberg
|
Chief Medical Officer |
Sale of securities on an exchange or to another person at price $ 40.00 per share. |
09 Jul 2026 |
10,000 |
119,763
(0%)
|
0%
|
40 |
400,000
|
Ordinary Shares |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 135.42 per share. |
09 Jul 2026 |
9,500 |
50,013
(0%)
|
0%
|
135.4 |
1,286,490
|
Common Stock |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
09 Jul 2026 |
9,500 |
30,218
|
-
|
|
-
|
Stock Option |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Sale of securities on an exchange or to another person at price $ 551.03 per share. |
09 Jul 2026 |
2,863 |
43,722
(0%)
|
0%
|
551.0 |
1,577,611
|
Common Stock |
|
Twist Bioscience Corp
|
Adam Laponis
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 94.33 per share. |
09 Jul 2026 |
2,399 |
110,276
(0%)
|
0%
|
94.3 |
226,307
|
Common Stock |
|
Mineralys Therapeutics Inc
|
David Rodman
|
Chief Medical Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.00 per share. |
09 Jul 2026 |
2,171 |
59,904
|
-
|
16 |
34,736
|
Common Stock |
|
Mineralys Therapeutics Inc
|
David Rodman
|
Chief Medical Officer |
Sale of securities on an exchange or to another person at price $ 30.30 per share. |
09 Jul 2026 |
2,171 |
57,733
|
-
|
30.3 |
65,781
|
Common Stock |
|
Mineralys Therapeutics Inc
|
David Rodman
|
Chief Medical Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
09 Jul 2026 |
2,171 |
15,194
|
-
|
|
-
|
Stock Option |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Sale of securities on an exchange or to another person at price $ 552.38 per share. |
09 Jul 2026 |
1,648 |
42,074
(0%)
|
0%
|
552.4 |
910,323
|
Common Stock |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Sale of securities on an exchange or to another person at price $ 549.01 per share. |
09 Jul 2026 |
1,536 |
48,037
(0%)
|
0%
|
549.0 |
843,273
|
Common Stock |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Sale of securities on an exchange or to another person at price $ 550.12 per share. |
09 Jul 2026 |
1,452 |
46,585
(0%)
|
0%
|
550.1 |
798,780
|
Common Stock |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Sale of securities on an exchange or to another person at price $ 553.29 per share. |
09 Jul 2026 |
801 |
41,273
(0%)
|
0%
|
553.3 |
443,185
|
Common Stock |
|
United Therapeutics Corp
|
Jan Malcolm
|
Director |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
09 Jul 2026 |
650 |
0
|
-
|
|
-
|
Restricted Stock Unit |
|
United Therapeutics Corp
|
Jan Malcolm
|
Director |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
09 Jul 2026 |
650 |
775
(0%)
|
0%
|
|
0
|
Common Stock |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Sale of securities on an exchange or to another person at price $ 554.22 per share. |
09 Jul 2026 |
640 |
40,633
(0%)
|
0%
|
554.2 |
354,704
|
Common Stock |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Sale of securities on an exchange or to another person at price $ 548.16 per share. |
09 Jul 2026 |
440 |
49,573
(0%)
|
0%
|
548.2 |
241,189
|
Common Stock |
|
United Therapeutics Corp
|
Jan Malcolm
|
Director |
Sale of securities on an exchange or to another person at price $ 550.59 per share. |
09 Jul 2026 |
325 |
450
(0%)
|
0%
|
550.6 |
178,942
|
Common Stock |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Sale of securities on an exchange or to another person at price $ 555.77 per share. |
09 Jul 2026 |
120 |
40,513
(0%)
|
0%
|
555.8 |
66,692
|
Common Stock |
|
Apogee Therapeutics Inc
|
Michael Henderson
|
Director, Chief Executive Officer |
Gift of securities by or to the insider at price $ 0.00 per share. |
08 Jul 2026 |
75,046 |
920,941
|
-
|
|
0
|
Common Stock |
|
Seres Therapeutics Inc
|
Richard N. Kender
|
Director, See Remarks |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
08 Jul 2026 |
50,000 |
50,000
|
-
|
|
-
|
Stock Option (right to buy) |
|
Syndax Pharma Inc
|
Michael Metzger
|
Director, Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 24.24 per share. |
08 Jul 2026 |
32,375 |
484,843
(1%)
|
0%
|
24.2 |
784,776
|
Common Stock |
|
Syndax Pharma Inc
|
Michael Metzger
|
Director, Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
08 Jul 2026 |
32,375 |
0
|
-
|
|
-
|
Stock Option (Right to buy) |
|
Syndax Pharma Inc
|
Michael Metzger
|
Director, Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.38 per share. |
08 Jul 2026 |
32,375 |
517,218
(1%)
|
0%
|
6.4 |
206,553
|
Common Stock |
|
Maravai LifeSciences Holdings Inc (Class A)
|
Bernd Brust
|
Director, Chief Executive Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.92 per share. |
08 Jul 2026 |
29,250 |
1,619,749
|
-
|
5.9 |
173,160
|
Class A Common Stock |
|
Seres Therapeutics Inc
|
Matthew Henn
|
See Remarks |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
08 Jul 2026 |
25,000 |
25,000
|
-
|
|
-
|
Stock Option (right to buy) |
|
Apogee Therapeutics Inc
|
Michael Henderson
|
Director, Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 133.63 per share. |
08 Jul 2026 |
20,000 |
995,987
|
-
|
133.6 |
2,672,600
|
Common Stock |
|
Seres Therapeutics Inc
|
Kelly Brady
|
See Remarks |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
08 Jul 2026 |
18,750 |
18,750
|
-
|
|
-
|
Stock Option (right to buy) |
|
Seer Inc (Class A)
|
Dipchand Nishar
|
Director |
Sale of securities on an exchange or to another person at price $ 2.18 per share. |
08 Jul 2026 |
10,660 |
59,044
|
-
|
2.2 |
23,265
|
Class A Common Stock |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
08 Jul 2026 |
9,500 |
39,718
|
-
|
|
-
|
Stock Option |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 135.42 per share. |
08 Jul 2026 |
9,500 |
50,013
(0%)
|
0%
|
135.4 |
1,286,490
|
Common Stock |
|
Seres Therapeutics Inc
|
Thomas J. DesRosier
|
See Remarks |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
08 Jul 2026 |
7,500 |
7,500
|
-
|
|
-
|
Stock Option (right to buy) |
|
Seres Therapeutics Inc
|
Marella Thorell
|
See Remarks |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
08 Jul 2026 |
7,500 |
7,500
|
-
|
|
-
|
Stock Option (right to buy) |
|
Moderna
|
Michael R. Mcdonnell
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
08 Jul 2026 |
7,415 |
7,415
|
-
|
|
-
|
Stock Option (Right to Buy) |
|
Janux Therapeutics Inc
|
David Campbell
|
Director, President and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.21 per share. |
08 Jul 2026 |
7,000 |
388,582
|
-
|
4.2 |
29,470
|
Common Stock |
|
Janux Therapeutics Inc
|
David Campbell
|
Director, President and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
08 Jul 2026 |
7,000 |
697,550
|
-
|
|
-
|
Stock Option (right to buy) |
|
Seres Therapeutics Inc
|
Kurt C. Graves
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
08 Jul 2026 |
6,500 |
6,500
|
-
|
|
-
|
Stock Option (right to buy) |
|
Seres Therapeutics Inc
|
Willard H. Dere
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
08 Jul 2026 |
6,500 |
6,500
|
-
|
|
-
|
Stock Option (right to buy) |
|
Seres Therapeutics Inc
|
Dennis A. Ausiello
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
08 Jul 2026 |
6,500 |
6,500
|
-
|
|
-
|
Stock Option (right to buy) |
|
Seres Therapeutics Inc
|
Robert L. Rosiello
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
08 Jul 2026 |
6,500 |
6,500
|
-
|
|
-
|
Stock Option (right to buy) |
|
Seres Therapeutics Inc
|
Eric D. Shaff
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
08 Jul 2026 |
6,500 |
6,500
|
-
|
|
-
|
Stock Option (right to buy) |
|
Seres Therapeutics Inc
|
Stephen A. Berenson
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
08 Jul 2026 |
6,500 |
6,500
|
-
|
|
-
|
Stock Option (right to buy) |
|
Moderna
|
Michael R. Mcdonnell
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
08 Jul 2026 |
5,733 |
5,733
|
-
|
|
-
|
Restricted Stock Units |
|
BioCardia Inc
|
Peter Altman
|
Director, President and CEO |
Purchase of securities on an exchange or from another person at price $ 0.97 per share. |
08 Jul 2026 |
5,500 |
367,485
(5%)
|
0%
|
1.0 |
5,335
|
Common Stock |
|
BioCardia Inc
|
Peter Altman
|
Director, President and CEO |
Purchase of securities on an exchange or from another person at price $ 0.96 per share. |
08 Jul 2026 |
5,400 |
361,985
(5%)
|
0%
|
1.0 |
5,208
|
Common Stock |
|
Contineum Therapeutics Inc (Class A)
|
Carmine N. Stengone
|
Director, CEO and President |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
08 Jul 2026 |
2,500 |
279,430
|
-
|
|
-
|
Stock Option (right to buy) |
|
Contineum Therapeutics Inc (Class A)
|
Carmine N. Stengone
|
Director, CEO and President |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.01 per share. |
08 Jul 2026 |
2,500 |
19,717
|
-
|
1.0 |
2,525
|
Class A Common Stock |
|
Contineum Therapeutics Inc (Class A)
|
Carmine N. Stengone
|
Director, CEO and President |
Sale of securities on an exchange or to another person at price $ 16.00 per share. |
08 Jul 2026 |
2,500 |
17,217
|
-
|
16 |
40,000
|
Class A Common Stock |
|
Immunovant Inc
|
Melanie Gloria
|
Chief Operating Officer |
Sale of securities on an exchange or to another person at price $ 39.53 per share. |
08 Jul 2026 |
1,930 |
222,463
(0%)
|
0%
|
39.5 |
76,293
|
Common Stock |
|
Halozyme Therapeutics Inc
|
Helen I. Torley
|
Director, PRESIDENT AND CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.07 per share. |
08 Jul 2026 |
1,923 |
769,703
(0%)
|
0%
|
12.1 |
23,211
|
Common Stock |
|
Halozyme Therapeutics Inc
|
Helen I. Torley
|
Director, PRESIDENT AND CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
08 Jul 2026 |
1,923 |
0
|
-
|
|
-
|
Option to Purchase Common Stock |
|
Immunovant Inc
|
Jay S. Stout
|
Chief Technology Officer |
Sale of securities on an exchange or to another person at price $ 39.53 per share. |
08 Jul 2026 |
1,906 |
209,779
(0%)
|
0%
|
39.5 |
75,344
|
Common Stock |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Sale of securities on an exchange or to another person at price $ 553.42 per share. |
08 Jul 2026 |
1,710 |
43,543
(0%)
|
0%
|
553.4 |
946,350
|
Common Stock |
|
Moderna
|
Michael R. Mcdonnell
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
08 Jul 2026 |
1,618 |
1,618
|
-
|
|
-
|
Restricted Stock Units |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Sale of securities on an exchange or to another person at price $ 552.51 per share. |
08 Jul 2026 |
1,490 |
45,253
(0%)
|
0%
|
552.5 |
823,241
|
Common Stock |
|
Immunovant Inc
|
Jay S. Stout
|
Chief Technology Officer |
Sale of securities on an exchange or to another person at price $ 39.53 per share. |
08 Jul 2026 |
1,399 |
208,275
(0%)
|
0%
|
39.5 |
55,302
|
Common Stock |
|
Immunovant Inc
|
Christopher A. Van Tuyl
|
Chief Legal Officer |
Sale of securities on an exchange or to another person at price $ 39.53 per share. |
08 Jul 2026 |
1,143 |
179,454
(0%)
|
0%
|
39.5 |
45,183
|
Common Stock |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Sale of securities on an exchange or to another person at price $ 554.45 per share. |
08 Jul 2026 |
1,118 |
42,425
(0%)
|
0%
|
554.5 |
619,880
|
Common Stock |
|
Halozyme Therapeutics Inc
|
Helen I. Torley
|
Director, PRESIDENT AND CEO |
Sale of securities on an exchange or to another person at price $ 80.19 per share. |
08 Jul 2026 |
1,035 |
767,780
(0%)
|
0%
|
80.2 |
82,994
|
Common Stock |
|
Contineum Therapeutics Inc (Class A)
|
Daniel S. Lorrain
|
Chief Scientific Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.01 per share. |
08 Jul 2026 |
1,015 |
136,217
|
-
|
1.0 |
1,025
|
Class A Common Stock |
|
Contineum Therapeutics Inc (Class A)
|
Daniel S. Lorrain
|
Chief Scientific Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
08 Jul 2026 |
1,015 |
33,282
|
-
|
|
-
|
Stock Option (right to buy) |
|
Contineum Therapeutics Inc (Class A)
|
Daniel S. Lorrain
|
Chief Scientific Officer |
Sale of securities on an exchange or to another person at price $ 16.00 per share. |
08 Jul 2026 |
1,015 |
135,202
|
-
|
16 |
16,240
|
Class A Common Stock |
|
BioCardia Inc
|
Peter Altman
|
Director, President and CEO |
Purchase of securities on an exchange or from another person at price $ 0.94 per share. |
08 Jul 2026 |
1,000 |
369,485
(5%)
|
0%
|
0.9 |
940
|
Common Stock |
|
BioCardia Inc
|
Peter Altman
|
Director, President and CEO |
Purchase of securities on an exchange or from another person at price $ 0.90 per share. |
08 Jul 2026 |
1,000 |
368,485
(5%)
|
0%
|
0.9 |
900
|
Common Stock |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Sale of securities on an exchange or to another person at price $ 551.56 per share. |
08 Jul 2026 |
925 |
46,743
(0%)
|
0%
|
551.6 |
510,190
|
Common Stock |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Sale of securities on an exchange or to another person at price $ 549.52 per share. |
08 Jul 2026 |
923 |
48,453
(0%)
|
0%
|
549.5 |
507,210
|
Common Stock |
|
Halozyme Therapeutics Inc
|
Helen I. Torley
|
Director, PRESIDENT AND CEO |
Sale of securities on an exchange or to another person at price $ 79.28 per share. |
08 Jul 2026 |
888 |
768,815
(0%)
|
0%
|
79.3 |
70,397
|
Common Stock |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Sale of securities on an exchange or to another person at price $ 550.45 per share. |
08 Jul 2026 |
785 |
47,668
(0%)
|
0%
|
550.4 |
432,101
|
Common Stock |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Sale of securities on an exchange or to another person at price $ 557.82 per share. |
08 Jul 2026 |
702 |
41,053
(0%)
|
0%
|
557.8 |
391,591
|
Common Stock |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Sale of securities on an exchange or to another person at price $ 548.62 per share. |
08 Jul 2026 |
637 |
49,376
(0%)
|
0%
|
548.6 |
349,472
|
Common Stock |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Sale of securities on an exchange or to another person at price $ 556.64 per share. |
08 Jul 2026 |
379 |
41,755
(0%)
|
0%
|
556.6 |
210,967
|
Common Stock |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Sale of securities on an exchange or to another person at price $ 560.79 per share. |
08 Jul 2026 |
320 |
40,513
(0%)
|
0%
|
560.8 |
179,454
|
Common Stock |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Sale of securities on an exchange or to another person at price $ 555.75 per share. |
08 Jul 2026 |
291 |
42,134
(0%)
|
0%
|
555.8 |
161,724
|
Common Stock |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Sale of securities on an exchange or to another person at price $ 558.79 per share. |
08 Jul 2026 |
220 |
40,833
(0%)
|
0%
|
558.8 |
122,933
|
Common Stock |
|
Immunovant Inc
|
Melanie Gloria
|
Chief Operating Officer |
Sale of securities on an exchange or to another person at price $ 39.99 per share. |
08 Jul 2026 |
106 |
222,357
(0%)
|
0%
|
40.0 |
4,239
|
Common Stock |
|
Immunovant Inc
|
Jay S. Stout
|
Chief Technology Officer |
Sale of securities on an exchange or to another person at price $ 39.99 per share. |
08 Jul 2026 |
105 |
209,674
(0%)
|
0%
|
40.0 |
4,199
|
Common Stock |
|
Immunovant Inc
|
Jay S. Stout
|
Chief Technology Officer |
Sale of securities on an exchange or to another person at price $ 39.99 per share. |
08 Jul 2026 |
77 |
208,198
(0%)
|
0%
|
40.0 |
3,079
|
Common Stock |
|
Immunovant Inc
|
Christopher A. Van Tuyl
|
Chief Legal Officer |
Sale of securities on an exchange or to another person at price $ 39.98 per share. |
08 Jul 2026 |
63 |
179,391
(0%)
|
0%
|
40.0 |
2,519
|
Common Stock |
|
Contineum Therapeutics Inc (Class A)
|
Daniel S. Lorrain
|
Chief Scientific Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.00 per share. |
08 Jul 2026 |
25 |
135,227
|
-
|
1 |
25
|
Class A Common Stock |
|
Contineum Therapeutics Inc (Class A)
|
Daniel S. Lorrain
|
Chief Scientific Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
08 Jul 2026 |
25 |
33,257
|
-
|
|
-
|
Stock Option (right to buy) |
|
Contineum Therapeutics Inc (Class A)
|
Daniel S. Lorrain
|
Chief Scientific Officer |
Sale of securities on an exchange or to another person at price $ 16.00 per share. |
08 Jul 2026 |
25 |
135,202
|
-
|
16 |
400
|
Class A Common Stock |
|
Mesoblast Ltd (ADR)
|
James Michael OBrien
|
Chief Financial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
07 Jul 2026 |
650,000 |
650,000
|
-
|
|
-
|
Option (Right to buy) |
|
Curis Inc
|
James E. Dentzer
|
Director, President & CEO |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
07 Jul 2026 |
110,090 |
110,090
|
-
|
|
-
|
Employee stock option (right to buy) |
|
Sionna Therapeutics Inc
|
Peter A. Thompson
|
Director |
Sale of securities on an exchange or to another person at price $ 44.86 per share. |
07 Jul 2026 |
85,918 |
2,469,959
|
-
|
44.9 |
3,854,281
|
Common Stock |
|
Aura Biosciences Inc
|
Jeremy Bender
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
07 Jul 2026 |
60,000 |
60,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
|
Kymera Therapeutics Inc
|
Nello Mainolfi
|
Director, Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. |
07 Jul 2026 |
50,000 |
716,568
|
-
|
2.1 |
104,000
|
Common Stock |
|
Kymera Therapeutics Inc
|
Nello Mainolfi
|
Director, Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 119.00 per share. |
07 Jul 2026 |
50,000 |
666,568
|
-
|
119 |
5,950,000
|
Common Stock |
|
Curis Inc
|
Diantha Duvall
|
CFO |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
07 Jul 2026 |
48,285 |
48,285
|
-
|
|
-
|
Employee stock option (right to buy) |
|
Curis Inc
|
Jonathan B. Zung
|
CDO |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
07 Jul 2026 |
48,285 |
48,285
|
-
|
|
-
|
Employee stock option (right to buy) |
|
Relay Therapeutics Inc
|
Sanjiv K. Patel
|
Director, President and CEO |
Sale of securities on an exchange or to another person at price $ 19.58 per share. |
07 Jul 2026 |
48,199 |
615,898
|
-
|
19.6 |
943,736
|
Common Stock |
|
Kymera Therapeutics Inc
|
Nello Mainolfi
|
Director, Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
07 Jul 2026 |
45,559 |
90,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
|
Vor Biopharma Inc
|
David Zaccardelli
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
07 Jul 2026 |
42,658 |
42,658
|
-
|
|
-
|
Stock Option (Right to Buy) |
|
Recursion Pharma Inc (Class A)
|
Blake Borgeson
|
Director |
Sale of securities on an exchange or to another person at price $ 3.96 per share. |
07 Jul 2026 |
40,000 |
6,218,287
|
-
|
4.0 |
158,500
|
Class A Common Stock |
|
Vera Therapeutics Inc (Class A)
|
Marshall Fordyce
|
Director, PRESIDENT AND CEO |
Sale of securities on an exchange or to another person at price $ 42.07 per share. |
07 Jul 2026 |
32,550 |
164,694
|
-
|
42.1 |
1,369,496
|
Class A Common Stock |
|
Aura Biosciences Inc
|
Jeremy Bender
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
07 Jul 2026 |
30,000 |
30,000
|
-
|
|
0
|
Common Stock |
|
MeiraGTx Holdings PLC
|
Stuart Naylor
|
CHIEF SCI OFCR, OPHTHALMOLOGY |
Sale of securities on an exchange or to another person at price $ 14.90 per share. |
07 Jul 2026 |
25,112 |
640,846
(1%)
|
0%
|
14.9 |
374,169
|
Ordinary Shares |
|
Elanco Animal Health Inc
|
Robert M. VanHimbergen
|
EVP and CFO |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.64 per share. |
07 Jul 2026 |
15,336 |
133,316
(0%)
|
0%
|
24.6 |
377,879
|
Common Stock |
|
Vera Therapeutics Inc (Class A)
|
Marshall Fordyce
|
Director, PRESIDENT AND CEO |
Sale of securities on an exchange or to another person at price $ 42.86 per share. |
07 Jul 2026 |
10,500 |
154,194
|
-
|
42.9 |
450,007
|
Class A Common Stock |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 135.42 per share. |
07 Jul 2026 |
9,500 |
50,013
(0%)
|
0%
|
135.4 |
1,286,490
|
Common Stock |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
07 Jul 2026 |
9,500 |
49,218
|
-
|
|
-
|
Stock Option |
|
Neurocrine Biosciences Inc
|
Ingrid Delaet
|
Chief Regulatory Officer |
Sale of securities on an exchange or to another person at price $ 178.72 per share. |
07 Jul 2026 |
8,433 |
16,225
(0%)
|
0%
|
178.7 |
1,507,135
|
Common Stock |
|
Neurocrine Biosciences Inc
|
Ingrid Delaet
|
Chief Regulatory Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
07 Jul 2026 |
8,433 |
7,478
|
-
|
|
-
|
Non-Qualified Stock Option |
|
Neurocrine Biosciences Inc
|
Ingrid Delaet
|
Chief Regulatory Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 103.52 per share. |
07 Jul 2026 |
8,433 |
24,658
(0%)
|
0%
|
103.5 |
872,984
|
Common Stock |
|
Curis Inc
|
Kenneth I. Kaitin
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
07 Jul 2026 |
6,800 |
6,800
|
-
|
|
-
|
Non Qualified Stock Option |
|
Curis Inc
|
Marc Rubin
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
07 Jul 2026 |
6,800 |
6,800
|
-
|
|
-
|
Non Qualified Stock Option |
|
Curis Inc
|
Martyn D. Greenacre
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
07 Jul 2026 |
6,800 |
6,800
|
-
|
|
-
|
Non Qualified Stock Option |
|
Curis Inc
|
John A. Hohneker
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
07 Jul 2026 |
6,800 |
6,800
|
-
|
|
-
|
Non Qualified Stock Option |
|
Kymera Therapeutics Inc
|
Nello Mainolfi
|
Director, Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
07 Jul 2026 |
4,441 |
14,284
|
-
|
|
-
|
Stock Option (Right to Buy) |
|
Neurocrine Biosciences Inc
|
Ingrid Delaet
|
Chief Regulatory Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
07 Jul 2026 |
3,401 |
18,648
|
-
|
|
-
|
Non-Qualified Stock Option |
|
Neurocrine Biosciences Inc
|
Ingrid Delaet
|
Chief Regulatory Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 103.52 per share. |
07 Jul 2026 |
3,401 |
19,626
(0%)
|
0%
|
103.5 |
352,072
|
Common Stock |
|
Neurocrine Biosciences Inc
|
Ingrid Delaet
|
Chief Regulatory Officer |
Sale of securities on an exchange or to another person at price $ 178.57 per share. |
07 Jul 2026 |
3,401 |
16,225
(0%)
|
0%
|
178.6 |
607,305
|
Common Stock |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Sale of securities on an exchange or to another person at price $ 559.76 per share. |
07 Jul 2026 |
3,399 |
41,880
(0%)
|
0%
|
559.8 |
1,902,629
|
Common Stock |
|
Relay Therapeutics Inc
|
Sanjiv K. Patel
|
Director, President and CEO |
Grant, award, or other acquisition of securities at price $ 6.95 per share. |
07 Jul 2026 |
3,056 |
664,097
|
-
|
6.9 |
21,239
|
Common Stock |
|
Neurocrine Biosciences Inc
|
Ingrid Delaet
|
Chief Regulatory Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
07 Jul 2026 |
2,737 |
15,911
|
-
|
|
-
|
Non-Qualified Stock Option |
|
Neurocrine Biosciences Inc
|
Ingrid Delaet
|
Chief Regulatory Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 103.52 per share. |
07 Jul 2026 |
2,737 |
18,962
(0%)
|
0%
|
103.5 |
283,334
|
Common Stock |
|
Neurocrine Biosciences Inc
|
Ingrid Delaet
|
Chief Regulatory Officer |
Sale of securities on an exchange or to another person at price $ 178.54 per share. |
07 Jul 2026 |
2,737 |
16,225
(0%)
|
0%
|
178.5 |
488,672
|
Common Stock |
|
MeiraGTx Holdings PLC
|
Stuart Naylor
|
CHIEF SCI OFCR, OPHTHALMOLOGY |
Sale of securities on an exchange or to another person at price $ 13.86 per share. |
07 Jul 2026 |
2,547 |
665,958
(1%)
|
0%
|
13.9 |
35,301
|
Ordinary Shares |
|
Vera Therapeutics Inc (Class A)
|
Marshall Fordyce
|
Director, PRESIDENT AND CEO |
Sale of securities on an exchange or to another person at price $ 43.59 per share. |
07 Jul 2026 |
2,200 |
151,994
|
-
|
43.6 |
95,908
|
Class A Common Stock |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Sale of securities on an exchange or to another person at price $ 558.90 per share. |
07 Jul 2026 |
1,875 |
45,279
(0%)
|
0%
|
558.9 |
1,047,938
|
Common Stock |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Sale of securities on an exchange or to another person at price $ 557.78 per share. |
07 Jul 2026 |
1,096 |
47,154
(0%)
|
0%
|
557.8 |
611,324
|
Common Stock |
|
Immunome Inc
|
Kinney Horn
|
CHIEF BUSINESS OFFICER |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
07 Jul 2026 |
1,092 |
128,908
|
-
|
|
-
|
Employee Stock Option (right to buy) |
|
Immunome Inc
|
Kinney Horn
|
CHIEF BUSINESS OFFICER |
Sale of securities on an exchange or to another person at price $ 25.00 per share. |
07 Jul 2026 |
1,092 |
0
|
-
|
25 |
27,300
|
Common Stock |
|
Immunome Inc
|
Kinney Horn
|
CHIEF BUSINESS OFFICER |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.92 per share. |
07 Jul 2026 |
1,092 |
1,092
|
-
|
12.9 |
14,109
|
Common Stock |
|
Vera Therapeutics Inc (Class A)
|
Marshall Fordyce
|
Director, PRESIDENT AND CEO |
Sale of securities on an exchange or to another person at price $ 40.78 per share. |
07 Jul 2026 |
1,000 |
197,244
|
-
|
40.8 |
40,776
|
Class A Common Stock |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Sale of securities on an exchange or to another person at price $ 562.60 per share. |
07 Jul 2026 |
800 |
40,575
(0%)
|
0%
|
562.6 |
450,077
|
Common Stock |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Sale of securities on an exchange or to another person at price $ 556.55 per share. |
07 Jul 2026 |
726 |
48,250
(0%)
|
0%
|
556.6 |
404,058
|
Common Stock |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Sale of securities on an exchange or to another person at price $ 555.50 per share. |
07 Jul 2026 |
596 |
48,976
(0%)
|
0%
|
555.5 |
331,079
|
Common Stock |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Sale of securities on an exchange or to another person at price $ 560.49 per share. |
07 Jul 2026 |
505 |
41,375
(0%)
|
0%
|
560.5 |
283,048
|
Common Stock |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Sale of securities on an exchange or to another person at price $ 554.36 per share. |
07 Jul 2026 |
241 |
49,572
(0%)
|
0%
|
554.4 |
133,600
|
Common Stock |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Sale of securities on an exchange or to another person at price $ 553.12 per share. |
07 Jul 2026 |
200 |
49,813
(0%)
|
0%
|
553.1 |
110,623
|
Common Stock |
|
Disc Medicine Inc
|
Jonathan Yu
|
Chief Operating Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.50 per share. |
07 Jul 2026 |
100 |
54,424
|
-
|
13.5 |
1,350
|
Common Stock |
|
Disc Medicine Inc
|
Jonathan Yu
|
Chief Operating Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
07 Jul 2026 |
100 |
23,747
|
-
|
|
-
|
Stock Option (Right to Buy) |
|
Disc Medicine Inc
|
Jonathan Yu
|
Chief Operating Officer |
Sale of securities on an exchange or to another person at price $ 82.50 per share. |
07 Jul 2026 |
100 |
54,324
|
-
|
82.5 |
8,250
|
Common Stock |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Sale of securities on an exchange or to another person at price $ 563.24 per share. |
07 Jul 2026 |
62 |
40,513
(0%)
|
0%
|
563.2 |
34,921
|
Common Stock |
|
Longeveron Inc (Class A)
|
Joshua M. Hare
|
Director, Chief Scientific Officer, Ten Percent Owner |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
06 Jul 2026 |
600,000 |
1,321,796
|
-
|
|
0
|
Class B Common Stock |
|
Longeveron Inc (Class A)
|
Joshua M. Hare
|
Director, Chief Scientific Officer, Ten Percent Owner |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
06 Jul 2026 |
400,000 |
400,000
|
-
|
|
-
|
Stock Option (right to buy) |
|
Candel Therapeutics Inc
|
Mark E. Sims
|
Chief Commercial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
06 Jul 2026 |
285,000 |
285,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
|
Dyne Therapeutics Inc
|
Jason P. Rhodes
|
Director |
Sale of securities on an exchange or to another person at price $ 22.79 per share. |
06 Jul 2026 |
253,039 |
4,223,448
|
-
|
22.8 |
5,766,759
|
Common Stock |
|
Dyne Therapeutics Inc
|
Jason P. Rhodes
|
Director |
Sale of securities on an exchange or to another person at price $ 22.79 per share. |
06 Jul 2026 |
127,182 |
1,217,537
|
-
|
22.8 |
2,898,478
|
Common Stock |
|
Dyne Therapeutics Inc
|
Jason P. Rhodes
|
Director |
Sale of securities on an exchange or to another person at price $ 23.17 per share. |
06 Jul 2026 |
124,379 |
4,099,069
|
-
|
23.2 |
2,881,861
|
Common Stock |
|
Mainz Biomed N.V.
|
Peter M. O’Rourke
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
06 Jul 2026 |
112,859 |
112,859
|
-
|
|
-
|
Stock Option (Right to Buy) |
|
Dyne Therapeutics Inc
|
Jason P. Rhodes
|
Director |
Sale of securities on an exchange or to another person at price $ 22.79 per share. |
06 Jul 2026 |
100,019 |
875,912
|
-
|
22.8 |
2,279,433
|
Common Stock |
|
Immunome Inc
|
Isaac Barchas
|
Director |
Sale of securities on an exchange or to another person at price $ 24.11 per share. |
06 Jul 2026 |
83,094 |
125,410
|
-
|
24.1 |
2,003,396
|
Common Stock |
|
Dyne Therapeutics Inc
|
Jason P. Rhodes
|
Director |
Sale of securities on an exchange or to another person at price $ 23.17 per share. |
06 Jul 2026 |
62,543 |
1,154,994
|
-
|
23.2 |
1,449,121
|
Common Stock |
|
Larimar Therapeutics Inc
|
Thomas Edward Hamilton
|
Director |
Purchase of securities on an exchange or from another person at price $ 3.34 per share. |
06 Jul 2026 |
50,000 |
714,798
|
-
|
3.3 |
166,890
|
Common Stock |
|
Dyne Therapeutics Inc
|
Jason P. Rhodes
|
Director |
Sale of securities on an exchange or to another person at price $ 23.17 per share. |
06 Jul 2026 |
49,193 |
826,719
|
-
|
23.2 |
1,139,802
|
Common Stock |
|
Dyne Therapeutics Inc
|
Jason P. Rhodes
|
Director |
Sale of securities on an exchange or to another person at price $ 23.62 per share. |
06 Jul 2026 |
29,587 |
4,069,482
|
-
|
23.6 |
698,845
|
Common Stock |
|
Xeris Biopharma Holdings Inc
|
Steven M. Pieper
|
See Remarks |
Sale of securities on an exchange or to another person at price $ 8.52 per share. |
06 Jul 2026 |
27,600 |
1,366,053
(5%)
|
0%
|
8.5 |
235,276
|
Common Stock |
|
Relay Therapeutics Inc
|
Thomas Catinazzo
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 18.69 per share. |
06 Jul 2026 |
17,717 |
159,744
|
-
|
18.7 |
331,131
|
Common Stock |
|
Xeris Biopharma Holdings Inc
|
Steven M. Pieper
|
See Remarks |
Sale of securities on an exchange or to another person at price $ 8.50 per share. |
06 Jul 2026 |
17,400 |
1,393,653
(5%)
|
0%
|
8.5 |
147,900
|
Common Stock |
|
Immunome Inc
|
Isaac Barchas
|
Director |
Sale of securities on an exchange or to another person at price $ 24.20 per share. |
06 Jul 2026 |
16,906 |
108,504
|
-
|
24.2 |
409,125
|
Common Stock |
|
Dyne Therapeutics Inc
|
Jason P. Rhodes
|
Director |
Sale of securities on an exchange or to another person at price $ 23.62 per share. |
06 Jul 2026 |
14,844 |
1,140,150
|
-
|
23.6 |
350,615
|
Common Stock |
|
Dyne Therapeutics Inc
|
Jason P. Rhodes
|
Director |
Sale of securities on an exchange or to another person at price $ 23.62 per share. |
06 Jul 2026 |
11,665 |
815,054
|
-
|
23.6 |
275,527
|
Common Stock |
|
Sionna Therapeutics Inc
|
Jennifer Fitzpatrick
|
Chief Legal Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
06 Jul 2026 |
10,250 |
40,685
|
-
|
|
-
|
Non-Qualified Stock Option (right to buy) |
|
Sionna Therapeutics Inc
|
Jennifer Fitzpatrick
|
Chief Legal Officer |
Sale of securities on an exchange or to another person at price $ 43.60 per share. |
06 Jul 2026 |
10,250 |
0
|
-
|
43.6 |
446,862
|
Common Stock |
|
Sionna Therapeutics Inc
|
Jennifer Fitzpatrick
|
Chief Legal Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.11 per share. |
06 Jul 2026 |
10,250 |
10,250
|
-
|
6.1 |
62,628
|
Common Stock |
|
Vaxcyte Inc
|
Andrew L. Guggenhime
|
PRESIDENT AND CFO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.35 per share. |
06 Jul 2026 |
10,000 |
114,395
|
-
|
5.4 |
53,500
|
Common Stock |
|
Vaxcyte Inc
|
Andrew L. Guggenhime
|
PRESIDENT AND CFO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
06 Jul 2026 |
10,000 |
226,827
|
-
|
|
-
|
Stock Option (right to buy) |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 135.42 per share. |
06 Jul 2026 |
9,500 |
50,013
(0%)
|
0%
|
135.4 |
1,286,490
|
Common Stock |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
06 Jul 2026 |
9,500 |
58,718
|
-
|
|
-
|
Stock Option |
|
Relay Therapeutics Inc
|
Donald A. Bergstrom
|
President, R&D |
Sale of securities on an exchange or to another person at price $ 18.71 per share. |
06 Jul 2026 |
8,660 |
409,897
|
-
|
18.7 |
162,029
|
Common Stock |
|
BioCardia Inc
|
Jay M. Moyes
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
06 Jul 2026 |
8,000 |
23,573
|
-
|
|
-
|
Stock Option (right to buy) |
|
BioCardia Inc
|
Simon H. Stertzer
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
06 Jul 2026 |
8,000 |
23,573
|
-
|
|
-
|
Stock Option (right to buy) |
|
BioCardia Inc
|
Marvin Slosman
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
06 Jul 2026 |
8,000 |
20,000
|
-
|
|
-
|
Stock Option (right to buy) |
|
BioCardia Inc
|
Andrew Scott Blank
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
06 Jul 2026 |
8,000 |
23,313
|
-
|
|
-
|
Stock Option (right to buy) |
|
BioCardia Inc
|
Jim L. Allen
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
06 Jul 2026 |
8,000 |
23,313
|
-
|
|
-
|
Stock Option (right to buy) |
|
BioCardia Inc
|
Bill Facteau
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
06 Jul 2026 |
8,000 |
23,729
|
-
|
|
-
|
Stock Option (right to buy) |
|
Vaxcyte Inc
|
Andrew L. Guggenhime
|
PRESIDENT AND CFO |
Sale of securities on an exchange or to another person at price $ 57.16 per share. |
06 Jul 2026 |
7,913 |
106,482
|
-
|
57.2 |
452,283
|
Common Stock |
|
Sana biotech Inc
|
Hans Edgar Bishop
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
06 Jul 2026 |
6,297 |
5,854,800
|
-
|
|
0
|
Common Stock |
|
Monte Rosa Therapeutics Inc
|
Sharon Townson
|
Chief Scientific Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
06 Jul 2026 |
6,000 |
197,290
|
-
|
|
-
|
Stock Option (Right to Buy) |
|
Monte Rosa Therapeutics Inc
|
Sharon Townson
|
Chief Scientific Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.14 per share. |
06 Jul 2026 |
6,000 |
73,845
|
-
|
6.1 |
36,840
|
Common Stock |
|
Enliven Therapeutics Inc
|
Lori Anne Kunkel
|
Director |
Sale of securities on an exchange or to another person at price $ 50.84 per share. |
06 Jul 2026 |
5,889 |
41,884
|
-
|
50.8 |
299,421
|
Common Stock |
|
Monte Rosa Therapeutics Inc
|
Sharon Townson
|
Chief Scientific Officer |
Sale of securities on an exchange or to another person at price $ 23.25 per share. |
06 Jul 2026 |
5,600 |
68,245
|
-
|
23.2 |
130,197
|
Common Stock |
|
Dyne Therapeutics Inc
|
Jason P. Rhodes
|
Director |
Sale of securities on an exchange or to another person at price $ 23.61 per share. |
06 Jul 2026 |
5,000 |
2,962
|
-
|
23.6 |
118,050
|
Common Stock |
|
Neurogene Inc
|
Christine Mikail Cvijic
|
Director, President and CFO |
Sale of securities on an exchange or to another person at price $ 36.13 per share. |
06 Jul 2026 |
4,200 |
84,040
|
-
|
36.1 |
151,763
|
Common Stock |
|
Enliven Therapeutics Inc
|
Lori Anne Kunkel
|
Director |
Sale of securities on an exchange or to another person at price $ 49.98 per share. |
06 Jul 2026 |
4,111 |
47,773
|
-
|
50.0 |
205,482
|
Common Stock |
|
Rallybio Corp
|
Helen M. Boudreau
|
Director |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.38 per share. |
06 Jul 2026 |
3,562 |
6,542
|
-
|
2.4 |
8,478
|
Common Stock |
|
Rallybio Corp
|
Helen M. Boudreau
|
Director |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
06 Jul 2026 |
3,562 |
0
|
-
|
|
-
|
Option (Right to Buy) |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Sale of securities on an exchange or to another person at price $ 549.03 per share. |
06 Jul 2026 |
3,354 |
43,530
(0%)
|
0%
|
549.0 |
1,841,459
|
Common Stock |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Sale of securities on an exchange or to another person at price $ 549.87 per share. |
06 Jul 2026 |
2,116 |
41,414
(0%)
|
0%
|
549.9 |
1,163,515
|
Common Stock |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Sale of securities on an exchange or to another person at price $ 546.93 per share. |
06 Jul 2026 |
2,098 |
47,915
(0%)
|
0%
|
546.9 |
1,147,468
|
Common Stock |
|
Vaxcyte Inc
|
Andrew L. Guggenhime
|
PRESIDENT AND CFO |
Sale of securities on an exchange or to another person at price $ 57.76 per share. |
06 Jul 2026 |
2,087 |
104,395
|
-
|
57.8 |
120,553
|
Common Stock |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Sale of securities on an exchange or to another person at price $ 548.00 per share. |
06 Jul 2026 |
1,031 |
46,884
(0%)
|
0%
|
548 |
564,988
|
Common Stock |
|
Natera Inc
|
Matthew Rabinowitz
|
Director, EXECUTIVE CHAIRMAN |
Sale of securities on an exchange or to another person at price $ 280.00 per share. |
06 Jul 2026 |
1,000 |
4,000
(0%)
|
0%
|
280 |
280,000
|
Common Stock |
|
Neurogene Inc
|
Christine Mikail Cvijic
|
Director, President and CFO |
Sale of securities on an exchange or to another person at price $ 36.02 per share. |
06 Jul 2026 |
600 |
88,240
|
-
|
36.0 |
21,613
|
Common Stock |
|
Monte Rosa Therapeutics Inc
|
Sharon Townson
|
Chief Scientific Officer |
Sale of securities on an exchange or to another person at price $ 24.13 per share. |
06 Jul 2026 |
400 |
67,845
|
-
|
24.1 |
9,652
|
Common Stock |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Sale of securities on an exchange or to another person at price $ 550.78 per share. |
06 Jul 2026 |
329 |
41,085
(0%)
|
0%
|
550.8 |
181,205
|
Common Stock |
|
United Therapeutics Corp
|
Martine A. Rothblatt
|
Director, Chairperson & CEO |
Sale of securities on an exchange or to another person at price $ 553.91 per share. |
06 Jul 2026 |
306 |
40,513
(0%)
|
0%
|
553.9 |
169,495
|
Common Stock |
